Metabolic rewiring mechanisms in drug-resistant breast cancer cells
Schematic diagram of metabolic rewiring mechanisms in drug-resistant breast cancer cells. Drug-sensitive cells have lower methylation levels of PFKFB3, PKM2, and PHGDH, increasing polyubiquitination of PFKFB3, PHGDH, and FASN to reduce influx from the glycolytic system into the serine synthesizing pathway (top). PRMT1 methylates PFKFB3, PKM2, and PHGDH to determine the fate of the carbon source for fatty acid synthesis to support chemoresistance in TNBC (bottom). Arginine methylation of PHGDH (R20/54) stabilizes the enzyme to enhance the serine synthetic pathway and de novo fatty acid synthesis through augmentation of αKG coupled with a PSAT1-involving reaction. Enhanced fatty acid synthesis sustains enzyme activity by S-palmitoylation of PHGDH and FASN through de novo synthesis of palmitate, promoting positive feedback between the serine synthetic pathway and fatty acid synthesis to acquire malignant traits in TNBC. Blockade of this feedback system using the PRMT1 inhibitor MS023 or S-palmitoyltransferase inhibitor 2-Br-Pal unlocks chemoresistance to paclitaxel
Publication
PRMT1 Sustains De Novo Fatty Acid Synthesis by Methylating PHGDH to Drive Chemoresistance in Triple-Negative Breast Cancer (2024) Takehiro Yamamoto, et al. Cancer Res. 2024 Apr 01;84(7). Figure: F8.| Organism | Group | Word | Match | Source | NCBI Symbol | NCBI ID |
|---|---|---|---|---|---|---|
| Homo sapiens | Primates | PFKFB3 | PFKFB3 | ncbigene_symbol | PFKFB3 | 5209 |
| Homo sapiens | Primates | PHGDH | PHGDH | ncbigene_symbol | PHGDH | 26227 |
| Homo sapiens | Primates | PKM2 | PKM2 | ncbigene_synonym | PKM | 5315 |
| Homo sapiens | Primates | PKM2 | PKM2 | famplex_relations | PKLR | 5313 |
| Homo sapiens | Primates | Lac | LAC | ncbigene_synonym | LCT | 3938 |
| Homo sapiens | Primates | FASN | FASN | ncbigene_symbol | FASN | 2194 |
| Homo sapiens | Primates | PRMT1 | PRMT1 | ncbigene_symbol | PRMT1 | 3276 |
| Word | Match | MeSH | Name | ChEBI |
|---|---|---|---|---|
| Glucose | Glucose | aldehydo-D-glucose | chebi:42758 | |
| Lac | LAC | chebi:90184 | ||
| Glucose | Glucose | aldehydo-D-glucose | chebi:42758 | |
| Palmitate | palmitate | hexadecanoate | chebi:7896 | |
| Glu | Glu | 2-aminopentanedioic acid | chebi:18237 | |
| Gly | Gly | glycine | chebi:15428 | |
| Ser | Ser | L-serine residue | chebi:29999 | |
| Cys | Cys | cysteine | chebi:15356 | |
| Cystathionine | Cystathionine | 2-amino-4-[(2-amino-2-carboxyethyl)sulfanyl]butanoic acid | chebi:17755 | |
| Gly | Gly | glycine | chebi:15428 | |
| Ser | Ser | L-serine residue | chebi:29999 | |
| Lac | LAC | chebi:90184 | ||
| Palmitate | palmitate | hexadecanoate | chebi:7896 | |
| Cystathionine | Cystathionine | 2-amino-4-[(2-amino-2-carboxyethyl)sulfanyl]butanoic acid | chebi:17755 | |
| Glutathione | glutathione | glutathione | chebi:57925 | |
| Glutathione | glutathione | glutathione | chebi:57925 |
Disease mentions
| Word | Match | MeSH | Name | DOID |
|---|